Direct thrombectomy for stroke in the presence of absolute exclusion criteria for thrombolysis.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 25 04 2020
accepted: 20 07 2020
revised: 15 06 2020
pubmed: 28 7 2020
medline: 22 6 2021
entrez: 27 7 2020
Statut: ppublish

Résumé

Intravenous thrombolysis (IVT)-ineligible patients undergoing direct thrombectomy tended to have poorer functional outcome as compared with IVT-eligible patients undergoing bridging therapy. We aimed to assess radiological and functional outcomes in large vessel occlusion-related stroke patients receiving direct thrombectomy in the presence of absolute exclusion criteria for IVT vs relative exclusion criteria for IVT and vs non-exclusion criteria for IVT. A cohort study on prospectively collected data from 2282 patients enrolled in the Italian Registry of Endovascular Treatment in Acute Stroke cohort for treatment with direct thrombectomy (n = 486, absolute exclusion criteria for IVT alone; n = 384, absolute in combination with relative exclusion criteria for IVT; n = 777, relative exclusion criteria for IVT alone; n = 635, non-exclusion criteria for IVT). After adjustment for unbalanced variables (model 1), ORs for 3-month death was higher in the presence of absolute exclusion criteria for IVT alone (vs relative exclusion criteria for IVT alone) (1.595, 95% CI 1.042-2.440) and in the presence of absolute exclusion criteria for IVT alone (vs non-exclusion criteria for IVT) (1.235, 95% CI 1.014-1.504). After adjustment for predefined variables (model 2: age, sex, pre-stroke mRS ≤ 1, NIHSS, occlusion in the anterior circulation, onset-to-groin time, and procedure time), ORs for 3-month death was higher in the presence of absolute exclusion criteria for IVT alone (vs relative exclusion criteria for IVT alone) (1.235, 95% CI 1.014-1.504) and in the presence of absolute exclusion criteria for IVT alone (vs non-exclusion criteria for IVT) (1.246, 95% CI 1.039-1.495). No significant difference was found between the groups as regards any type of intracerebral hemorrhage and parenchymal hematoma within 24 h, successful and complete recanalization after procedure, and modified Rankin Scale score 0-2 at 3 months. After adjustment for predefined variables of model 2, ORs for death were higher in the presence of recent administration of IV heparin (OR: 2.077), platelet count < 100,000/mm Radiological outcomes were similar after direct thrombectomy in patients with absolute, relative, and non- exclusion criteria for IVT, while an increase of fatal outcome was observed in the presence of some absolute exclusion criterion for IVT.

Sections du résumé

BACKGROUND BACKGROUND
Intravenous thrombolysis (IVT)-ineligible patients undergoing direct thrombectomy tended to have poorer functional outcome as compared with IVT-eligible patients undergoing bridging therapy. We aimed to assess radiological and functional outcomes in large vessel occlusion-related stroke patients receiving direct thrombectomy in the presence of absolute exclusion criteria for IVT vs relative exclusion criteria for IVT and vs non-exclusion criteria for IVT.
METHODS METHODS
A cohort study on prospectively collected data from 2282 patients enrolled in the Italian Registry of Endovascular Treatment in Acute Stroke cohort for treatment with direct thrombectomy (n = 486, absolute exclusion criteria for IVT alone; n = 384, absolute in combination with relative exclusion criteria for IVT; n = 777, relative exclusion criteria for IVT alone; n = 635, non-exclusion criteria for IVT).
RESULTS RESULTS
After adjustment for unbalanced variables (model 1), ORs for 3-month death was higher in the presence of absolute exclusion criteria for IVT alone (vs relative exclusion criteria for IVT alone) (1.595, 95% CI 1.042-2.440) and in the presence of absolute exclusion criteria for IVT alone (vs non-exclusion criteria for IVT) (1.235, 95% CI 1.014-1.504). After adjustment for predefined variables (model 2: age, sex, pre-stroke mRS ≤ 1, NIHSS, occlusion in the anterior circulation, onset-to-groin time, and procedure time), ORs for 3-month death was higher in the presence of absolute exclusion criteria for IVT alone (vs relative exclusion criteria for IVT alone) (1.235, 95% CI 1.014-1.504) and in the presence of absolute exclusion criteria for IVT alone (vs non-exclusion criteria for IVT) (1.246, 95% CI 1.039-1.495). No significant difference was found between the groups as regards any type of intracerebral hemorrhage and parenchymal hematoma within 24 h, successful and complete recanalization after procedure, and modified Rankin Scale score 0-2 at 3 months. After adjustment for predefined variables of model 2, ORs for death were higher in the presence of recent administration of IV heparin (OR: 2.077), platelet count < 100,000/mm
CONCLUSIONS CONCLUSIONS
Radiological outcomes were similar after direct thrombectomy in patients with absolute, relative, and non- exclusion criteria for IVT, while an increase of fatal outcome was observed in the presence of some absolute exclusion criterion for IVT.

Identifiants

pubmed: 32712865
doi: 10.1007/s00415-020-10098-w
pii: 10.1007/s00415-020-10098-w
doi:

Substances chimiques

Fibrinolytic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3731-3740

Auteurs

Manuel Cappellari (M)

USD Stroke Unit, DAI di Neuroscienze, Azienda Ospedaliera Universitaria Integrata, Piazzale A. Stefani 1, 37126, Verona, Italy. manuel_cappellari@libero.it.

Giovanni Pracucci (G)

University of Florence, Firenze, Italy.

Stefano Forlivesi (S)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Maggiore Hospital, Bologna, Italy.

Valentina Saia (V)

Santa Corona Hospital, Pietra Ligure, Italy.

Nicola Limbucci (N)

Careggi University Hospital, Firenze, Italy.

Patrizia Nencini (P)

Careggi University Hospital, Firenze, Italy.

Domenico Inzitari (D)

University of Florence, Firenze, Italy.

Valerio Da Ros (V)

Policlinico Tor Vergata, Rome, Italy.

Fabrizio Sallustio (F)

Policlinico Tor Vergata, Rome, Italy.

Stefano Vallone (S)

Ospedale Civile S.Agostino-Estense-University Hospital, Modena, Italy.

Guido Bigliardi (G)

Ospedale Civile S.Agostino-Estense-University Hospital, Modena, Italy.

Andrea Zini (A)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Maggiore Hospital, Bologna, Italy.

Sergio Lucio Vinci (SL)

Policlinico G. Martino, Messina, Italy.

Cristina Dell'Aera (C)

Policlinico G. Martino, Messina, Italy.

Sandra Bracco (S)

Ospedale S. Maria delle Scotte-University Hospital, Siena, Italy.

Samuele Cioni (S)

Ospedale S. Maria delle Scotte-University Hospital, Siena, Italy.

Rossana Tassi (R)

Ospedale S. Maria delle Scotte-University Hospital, Siena, Italy.

Mauro Bergui (M)

Città della Salute e della Scienza-Molinette, Turin, Italy.

Andrea Naldi (A)

Città della Salute e della Scienza-Molinette, Turin, Italy.

Giuseppe Carità (G)

Arcispedale S. Anna-University Hospital, Ferrara, Italy.

Cristiano Azzini (C)

Arcispedale S. Anna-University Hospital, Ferrara, Italy.

Ilaria Casetta (I)

Arcispedale S. Anna-University Hospital, Ferrara, Italy.

Roberto Gasparotti (R)

Spedali Civili, Brescia, Italy.

Mauro Magoni (M)

Spedali Civili, Brescia, Italy.

Lucio Castellan (L)

IRCCS San Martino-IST, Genoa, Italy.

Cinzia Finocchi (C)

IRCCS San Martino-IST, Genoa, Italy.

Roberto Menozzi (R)

Ospedale Universitario, Parma, Italy.

Umberto Scoditti (U)

Ospedale Universitario, Parma, Italy.

Francesco Causin (F)

Azienda Ospedaliero-Univeristaria, Padua, Italy.

Federica Viaro (F)

Azienda Ospedaliero-Univeristaria, Padua, Italy.

Edoardo Puglielli (E)

Ospedale Civile Mazzini, Teramo, Italy.

Alfonsina Casalena (A)

Ospedale Civile Mazzini, Teramo, Italy.

Maria Ruggiero (M)

Ospedale M. Bufalini, Cesena, Italy.

Sara Biguzzi (S)

Ospedale M. Bufalini, Cesena, Italy.

Davide Castellano (D)

Ospedale San Giovanni Bosco, Turin, Italy.

Roberto Cavallo (R)

Ospedale San Giovanni Bosco, Turin, Italy.

Guido Andrea Lazzarotti (GA)

Ospedale Cisanello, Pisa, Italy.

Giovanni Orlandi (G)

Ospedale Cisanello, Pisa, Italy.

Alessandro Sgreccia (A)

Policlinico IRCCS San Matteo, Pavia, Italy.

Maria Federica Denaro (MF)

IRCCS Mondino Foundation, Pavia, Italy.

Nicola Cavasin (N)

Ospedale dell'Angelo-USSL3 Serenissima, Mestre, Italy.

Adriana Critelli (A)

Ospedale dell'Angelo-USSL3 Serenissima, Mestre, Italy.

Elisa Francesca Maria Ciceri (EFM)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Bruno Bonetti (B)

USD Stroke Unit, DAI di Neuroscienze, Azienda Ospedaliera Universitaria Integrata, Piazzale A. Stefani 1, 37126, Verona, Italy.

Luigi Chiumarulo (L)

Azienda Ospedaliera Universitaria-Policlinico, Bari, Italy.

Marco Petruzzelli (M)

Azienda Ospedaliera Universitaria-Policlinico, Bari, Italy.

Carlo Pellegrino (C)

Ospedale Universitario Circolo-ASST Sette Laghi, Varese, Italy.

Federico Carimati (F)

Ospedale Universitario Circolo-ASST Sette Laghi, Varese, Italy.

Nicola Burdi (N)

Ospedale SS. Annunziata, Taranto, Italy.

Maria Pia Prontera (MP)

Ospedale SS. Annunziata, Taranto, Italy.

Wiliam Auteri (W)

Azienda Ospedaliera Annunziata, Cosenza, Italy.

Alfredo Petrone (A)

Azienda Ospedaliera Annunziata, Cosenza, Italy.

Giulio Guidetti (G)

Sapienza University Hospital, Rome, Italy.

Ettore Nicolini (E)

Sapienza University Hospital, Rome, Italy.

Giuseppe Ganci (G)

Santa Corona Hospital, Pietra Ligure, Italy.

Annalisa Sugo (A)

Santa Corona Hospital, Pietra Ligure, Italy.

Pietro Filauri (P)

Presidio Ospedaliero SS. Filippo e Nicola, Avezzano, Italy.

Simona Sacco (S)

Presidio Ospedaliero SS. Filippo e Nicola, Avezzano, Italy.

Guido Squassina (G)

Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy.

Paolo Invernizzi (P)

Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy.

Nunzio Paolo Nuzzi (NP)

Humanitas Research Hospital, Rozzano, Italy.

Manuel Corato (M)

Humanitas Research Hospital, Rozzano, Italy.

Pietro Amistà (P)

Ospedale S. Maria Misericordia, Rovigo, Italy.

Mauro Gentile (M)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Maggiore Hospital, Bologna, Italy.

Stefano Barbero (S)

AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy.

Federica Schirru (F)

Ospedale S. Michele-AO Brotzu, Cagliari, Italy.

Giuseppe Craparo (G)

Ospedale Civico-A.R.N.A.S., Palermo, Italy.

Marina Mannino (M)

Ospedale Civico-A.R.N.A.S., Palermo, Italy.

Luigi Simonetti (L)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Maggiore Hospital, Bologna, Italy.

Salvatore Mangiafico (S)

Careggi University Hospital, Firenze, Italy.

Danilo Toni (D)

Sapienza University Hospital, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH